About RQX Pharmaceuticals
RQX Pharmaceuticals is a company based in San Diego (United States) founded in 2010 was acquired by Genentech in February 2013. RQX Pharmaceuticals has raised $1.19 million across 1 funding round from investors including Genentech and Avalon Ventures. RQX Pharmaceuticals operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of RQX Pharmaceuticals
RQX Pharmaceuticals has successfully raised a total of $1.19M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.19 million completed in February 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in RQX Pharmaceuticals
RQX Pharmaceuticals has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Genentech and Avalon Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage venture capital is provided to US companies.
|
Locked | Locked | Locked | |
|
R&D company focused on manufacturing drugs for multiple therapeutic areas
|
Locked | Locked | Locked |
Investor details for RQX Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by RQX Pharmaceuticals
Investment portfolio details for RQX Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - RQX Pharmaceuticals
Detailed financials for RQX Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rqx Pharmaceuticals Comparisons
Peer comparison for RQX Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RQX Pharmaceuticals
RQX Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
Detailed competitors of RQX Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rqx Pharmaceuticals
Complete news archive for RQX Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RQX Pharmaceuticals
RQX Pharmaceuticals was founded in 2010 and raised its 1st funding round 1 year after it was founded.
RQX Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
RQX Pharmaceuticals is a funded company, having raised a total of $1.19M across 1 funding round to date.
RQx Pharmaceuticals develops broad-spectrum antibiotics. Focused on a novel molecular target for which no antibiotic has been developed. Additionally, the company has generated proprietary molecules based on a novel chemical scaffold. The companys initial products focussed on community and hospital-associated infections, including those from gram-negative bacteria. Was founded based on discoveries in Floyd Romesbergs lab at The Scripps Research Institute in La Jolla, CA. Genentech signed 111 million deal with the company to discover and develop compounds against an undisclosed target. RQx is a portfolio company of Avalon Ventures and also received investments from COI Pharmaceuticals.
RQX Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
RQX Pharmaceuticals has 2 investors. Key investors include Genentech, and Avalon Ventures.